Styrofoam cup maker Kenneth Dart's family office joins the consortium backing Portola Pharmaceuticals.

The US-based oncological research company has raised $78m in equity financing from investors including Celgene, taking its overall equity funding to $102m.

The Siemens-backed medical device company has agreed to raise $22.1m from its initial public offering, expected to take place later this week.

The biopharmaceutical company has launched a $50m technology and life sciences corporate venturing unit, according to its latest financial results.

The $50m life sciences fund was launched by GlaxoSmithKline last week, and will be partly run by its SR One corporate venturing unit.

The biotechnology firm has raised $20.1m in series C funding one week after filing for an initial public offering, taking its overall financing to $68.1m.

The oncological biopharmaceutical research company is looking to raise up to $50m from an initial public offering less than 18 months after its inception.